Sana Biotechnology is a biotechnology company, focusing on utilizing engineered cells as medicines. Co. is developing ex vivo and in vivo cell engineering platforms for treatment across therapeutic areas including oncology, diabetes, central nervous system disorders, cardiovascular diseases, and genetic disorders, among others. Co.'s ex vivo cell engineering pipeline includes its allogeneic T cell program that target CD19 to treat patients with refractory lymphoma. Co.'s in vivo cell engineering pipeline includes its CAR T cell fusosome product candidates (SG242, SG295) target CD19+ cancer cells, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. We show 15 historical shares outstanding datapoints in our coverage of SANA's shares outstanding history.
Understanding the changing numbers of SANA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SANA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SANA by allowing them to research SANA shares outstanding history
as well as any other stock in our coverage universe. |
Free SANA Email Alerts:
Video: Shares Outstanding Importance
